Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy

Barta JA, Powell CA, Wisnivesky JP (2019) Global epidemiology of lung cancer. Ann Glob Health 85(1):8. https://doi.org/10.5334/aogh.2419

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, KEYNOTE-001 Investigators (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–28. https://doi.org/10.1056/NEJMoa1501824

Article  PubMed  Google Scholar 

Garon EB (2016) The race for combined checkpoint inhibition in NSCLC. Lancet Oncol 17(3):259–260. https://doi.org/10.1016/S1470-2045(15)00580-X

Article  PubMed  Google Scholar 

Ellis PM, Vella ET, Ung YC (2017) Immune checkpoint inhibitors for patients with advanced non–small-cell lung cancer: a systematic review. Clin Lung Cancer 18(5):444-459.e1. https://doi.org/10.1016/j.cllc.2017.02.001

Article  CAS  PubMed  Google Scholar 

Garon EB, Hellmann MD, Rizvi NA et al (2019) Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I keynote-001 study. JCO JCO.19.00934. https://doi.org/10.1200/JCO.19.00934

Champiat S, Dercle L, Ammari S et al (2016) Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-16-1741

Article  PubMed  Google Scholar 

Qin A, Street L, Cease K et al (2017) Clinical determinants of durable clinical benefit of pembrolizumab in veterans with advanced non–small-cell lung cancer. Clin Lung Cancer 18(5):559–564. https://doi.org/10.1016/j.cllc.2017.01.012

Article  CAS  PubMed  PubMed Central  Google Scholar 

Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19(3):133–150. https://doi.org/10.1038/s41568-019-0116-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Y, Zhou S, Yang F et al (2019) Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.0393

Article  PubMed  PubMed Central  Google Scholar 

Georgieva M, da Silveira Nogueira Lima JP, Aguiar P, de Lima Lopes G, Haaland B (2018) Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer. Lung Cancer 124:248–254. https://doi.org/10.1016/j.lungcan.2018.08.018

Article  PubMed  Google Scholar 

Bodor JN, Boumber Y, Borghaei H (2020) Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC). Cancer 126(2):260–270. https://doi.org/10.1002/cncr.32468

Article  CAS  PubMed  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med 375(19):1823–1833. https://doi.org/10.1056/NEJMoa1606774

Article  CAS  PubMed  Google Scholar 

Antonia SJ, Villegas A, Daniel D et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379(24):2342–2350. https://doi.org/10.1056/NEJMoa1809697

Article  CAS  PubMed  Google Scholar 

Tsao MS, Kerr KM, Kockx M et al (2018) PD-L1 Immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol 13(9):1302–1311. https://doi.org/10.1016/j.jtho.2018.05.013

Article  PubMed  PubMed Central  Google Scholar 

Carbone DP, Reck M, Paz-Ares L et al (2017) First-line nivolumab in stage IV or recurrent non–small-cell lung cancer. N Engl J Med 376(25):2415–2426. https://doi.org/10.1056/NEJMoa1613493

Article  CAS  PubMed  PubMed Central  Google Scholar 

Horn L, Spigel DR, Vokes EE et al (2017) Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 35(35):3924–3933. https://doi.org/10.1200/JCO.2017.74.3062

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marcus L, Fashoyin-Aje LA, Donoghue M et al (2021) FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res 27(17):4685–4689. https://doi.org/10.1158/1078-0432.CCR-21-0327

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prasad V, Addeo A (2020) The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No. Ann Oncol 31(9):1112–1114. https://doi.org/10.1016/j.annonc.2020.07.001

Article  CAS  PubMed  Google Scholar 

Hellmann MD, Callahan MK, Awad MM et al (2018) Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell 33(5):853-861.e4. https://doi.org/10.1016/j.ccell.2018.04.001

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herbst RS, Giaccone G, de Marinis F et al (2020) Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC. N Engl J Med. https://doi.org/10.1056/NEJMoa1917346

Article  PubMed  Google Scholar 

Hellmann MD, Paz-Ares L, Bernabe Caro R et al (2019) Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med 381(21):2020–2031. https://doi.org/10.1056/NEJMoa1910231

Article  CAS  PubMed  Google Scholar 

Herbst RS, Soria J-C, Kowanetz M et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515(7528):563–567. https://doi.org/10.1038/nature14011

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu-Lieskovan S, Lisberg A, Zaretsky JM et al (2019) Tumor characteristics associated with benefit from pembrolizumab in advanced non–small cell lung cancer. Clin Cancer Res 25(16):5061–5068. https://doi.org/10.1158/1078-0432.CCR-18-4275

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mezquita L, Auclin E, Ferrara R et al (2018) Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol 4(3):351–357. https://doi.org/10.1001/jamaoncol.2017.4771

Article  PubMed  PubMed Central  Google Scholar 

Fehrenbacher L, Spira A, Ballinger M et al (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. The Lancet 387(10030):1837–1846. https://doi.org/10.1016/S0140-6736(16)00587-0

Article  CAS  Google Scholar 

Kamphorst AO, Pillai RN, Yang S et al (2017) Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients. PNAS 114(19):4993–4998. https://doi.org/10.1073/pnas.1705327114

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sanmamed MF, Carranza-Rua O, Alfaro C et al (2014) Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin Cancer Res 20(22):5697–5707. https://doi.org/10.1158/1078-0432.CCR-13-3203

Article  CAS  PubMed  Google Scholar 

Guibert N, Delaunay M, Lusque A et al (2018) PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer 120:108–112. https://doi.org/10.1016/j.lungcan.2018.04.001

Article  PubMed  Google Scholar 

Indini A, Rijavec E, Grossi F (2021) Circulating biomarkers of response and toxicity of immunotherapy in advanced non-small cell lung cancer (NSCLC): a comprehensive review. Cancers 13(8):1794. https://doi.org/10.3390/cancers13081794

Article  CAS  PubMed  PubMed Central  Google Scholar 

He X, Xu C (2020) Immune checkpoint signaling and cancer immunotherapy. Cell Res 30(8):660–669. https://doi.org/10.1038/s41422-020-0343-4

Article  PubMed  PubMed Central  Google Scholar 

Yarchoan M, Albacker LA, Hopkins AC et al (2019) PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 4(6):126908. https://doi.org/10.1172/jci.insight.126908

Article  PubMed  Google Scholar 

Lee J, Hyeon DY, Hwang D (2020) Single-cell multiomics: technologies and data analysis methods. Exp Mol Med 52(9):1428–1442. https://doi.org/10.1038/s12276-020-0420-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stuart T, Satija R (2019) Integrative single-cell analysis. Nat Rev Genet 20(5):257–272. https://doi.org/10.1038/s41576-019-0093-7

Article  CAS  PubMed  Google Scholar 

Hartmann FJ, Bendall SC (2020) Immune monitoring using mass cytometry and related high-dimensional imaging approaches. Nat Rev Rheumatol 16(2):87–99. https://doi.org/10.1038/s41584-019-0338-z

Article  PubMed  Google Scholar 

Philip M, Schietinger A (2019) Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections. Curr Opin Immunol 58:98–103. https://doi.org/10.1016/j.coi.2019.04.014

Article  CAS  PubMed  PubMed Central  Google Scholar 

Datar I, Sanmamed MF, Wang J et al (2019) Expression analysis and significance of PD-1, LAG-3 and TIM-3 in human non-small cell lung cancer using spatially-resolved and multiparametric single-cell analysis. Clin Cancer Res 25(15):4663–4673. https://doi.org/10.1158/1078-0432.CCR-18-4142

Article 

留言 (0)

沒有登入
gif